Positions

Overview

  • Steven M. Rowe was born in Baton Rouge, LA in May 1972. He received his BA degree from the University of Virginia in 1994, his medical degree from Vanderbilt University in 1998, and an MSPH from the University of Alabama at Birmingham in 2005. He completed a combined Internal Medicine and Pediatrics internship and residency at the University of Alabama at Birmingham. He also completed a combined Pulmonary and Critical Care Medicine and Pediatric Pulmonary fellowship at the University of Alabama at Birmingham.
    In 2014, Dr. Rowe was promoted to Professor with tenure in the Departments of Medicine (Pulmonary, Allergy, and Critical Care Medicine), Pediatrics (Pediatric Pulmonology), and Cell Developmental and Integrative Biology. He is the Director of the Gregory Fleming Cystic Fibrosis Research Center, which involves over 100 faculty members and has been continuously funded for over 25 years. Dr. Rowe is board certified in Internal Medicine, Pediatrics, Pulmonary Medicine and Critical Care Medicine and serves as a Special Consultant for Translational Science for the Cystic Fibrosis Foundation.
    Dr. Rowe has a remarkable ability to identify, establish, and cultivate effective collaborations across institutional and geographic boundaries. He established a prolific six-year collaboration with Dr. Guillermo Tearney to advance µOCT imaging for use in respiratory epithelia to ask seminal questions in airway biology. Dr. Rowe initiated an eight-year collaboration with Dr. Mark Dransfield to investigate acquired CFTR dysfunction in COPD. He has a seven-year collaboration with Dr. David Bedwell to advance translational readthrough approaches for genetic disease. Dr. Rowe is also highly effective in research consortia. He leads the International Mucus Clearance Consortium, involving Fundamental and translational scientists. He is also a key member of the cystic fibrosis research community, helping lead the Cystic Fibrosis Therapeutics Development Network through the Center for CFTR Detection.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 Through 11 Years of Age With CF and at Least One F508del Allele..  American Journal of Respiratory and Critical Care Medicine.  2021
    2021 Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.  Journal of Cystic Fibrosis.  20:213-219. 2021
    2021 Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.  Journal of Cystic Fibrosis.  20:333-338. 2021
    2021 PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.  Journal of Cystic Fibrosis.  20:205-212. 2021
    2021 Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).  Journal of Cystic Fibrosis.  20:250-256. 2021
    2021 Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.  Journal of Cystic Fibrosis.  20:228-233. 2021
    2021 Novel Correctors and Potentiators Enhance Functional Rescue of CFTR Nonsense Mutation Translational Readthrough..  American Journal of Respiratory Cell and Molecular Biology.  2021
    2021 Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial.  Annals of the American Thoracic Society.  18:75-83. 2021
    2021 Korean Red Ginseng aqueous extract improves markers of mucociliary clearance by stimulating chloride secretion.  Journal of Ginseng Research.  45:66-74. 2021
    2021 Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study 2021
    2021 Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.  Journal of Cystic Fibrosis.  2021
    2020 A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay.  Frontiers in Physiology.  11. 2020
    2020 Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.  Journal of Cystic Fibrosis.  19:931-933. 2020
    2020 G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations 2020
    2020 Ivacaftor reverses airway mucus abnormalities in a rat model harboring a humanized G551D-CFTR.  American Journal of Respiratory and Critical Care Medicine.  202:1271-1282. 2020
    2020 Novel therapy of bicarbonate, glutathione, and ascorbic acid improves cystic fibrosis mucus transport.  American Journal of Respiratory Cell and Molecular Biology.  63:362-373. 2020
    2020 Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis.  Journal of Cystic Fibrosis.  19:783-790. 2020
    2020 Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.  Journal of Cystic Fibrosis.  19:742-745. 2020
    2020 Transparency and diversity in cystic fibrosis research – Authors' reply 2020
    2020 Pharmacological approaches for targeting cystic fibrosis nonsense mutations 2020
    2020 Contribution of Short Chain Fatty Acids to the Growth of Pseudomonas aeruginosa in Rhinosinusitis.  Frontiers in Cellular and Infection Microbiology.  10. 2020
    2020 Fibroblast Growth Factor Receptor 4 Deficiency Mediates Airway Inflammation in the Adult Healthy Lung?.  Frontiers in Medicine.  7. 2020
    2020 Airway remodeling in ferrets with cigarette smoke-induced COPD using μCT imaging 2020
    2020 Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.  Pediatric Pulmonology.  55:1838-1842. 2020
    2020 Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).  Journal of Cystic Fibrosis.  19:595-601. 2020
    2020 CFTR targeted therapies: Recent advances in cystic fibrosis and possibilities in other diseases of the airways.  European Respiratory Review.  29:1-13. 2020
    2020 Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice.  JCI insight.  5. 2020
    2020 Human nasal epithelial organoids for therapeutic development in cystic fibrosis.  Genes.  11:1-17. 2020
    2020 Cystic fibrosis: Emergence of highly effective targeted therapeutics and potential clinical implications.  American Journal of Respiratory and Critical Care Medicine.  201:1193-1208. 2020
    2020 Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis.  International Forum of Allergy and Rhinology.  10:481-488. 2020
    2020 The impact of Lactococcus lactis (probiotic nasal rinse) co-culture on growth of patient-derived strains of Pseudomonas aeruginosa.  International Forum of Allergy and Rhinology.  10:444-449. 2020
    2020 Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?.  Neurology.  94:481-494. 2020
    2020 Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation. Reply.  New England Journal of Medicine.  382:684. 2020
    2020 Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: A cohort study.  PLoS ONE.  15. 2020
    2020 The Effects of the Anti-aging Protein Klotho on Mucociliary Clearance.  Frontiers in Medicine.  6. 2020
    2020 Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation.  Annals of the American Thoracic Society.  17:212-220. 2020
    2020 Efficacy and safety of the cftr potentiator icenticaftor (Qbw251) in copd: Results from a phase 2 randomized trial 2020
    2020 Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.  Journal of Cystic Fibrosis.  2020
    2020 Excess mucus viscosity and airway dehydration impact COPD airway clearance.  European Respiratory Journal.  55. 2020
    2020 Females with cystic fibrosis demonstrate a differential response profile to ivacaftor compared with males.  American Journal of Respiratory and Critical Care Medicine.  201:996-998. 2020
    2020 The future of cystic fibrosis care: a global perspective 2020
    2020 Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.  Journal of Cystic Fibrosis.  2020
    2019 Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia.  International Forum of Allergy and Rhinology.  9:1430-1435. 2019
    2019 Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial 2019
    2019 Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.  New England Journal of Medicine.  381:1809-1819. 2019
    2019 Area deprivation as a risk factor for methicillin-resistant Staphylococcus aureus infection in pediatric cystic fibrosis 2019
    2019 Co-cultured microfluidic model of the airway optimized for microscopy and micro-optical coherence tomography imaging.  Biomedical Optics Express.  10:5414-5430. 2019
    2019 Revealing the molecular signaling pathways of mucus stasis in cystic fibrosis.  Journal of Clinical Investigation.  129:4089-4090. 2019
    2019 Geometry-Dependent Spectroscopic Contrast in Deep Tissues.  iScience.  19:965-975. 2019
    2019 Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies.  Science Translational Medicine.  11. 2019
    2019 Vaporized e-cigarette liquids induce ion transport dysfunction in airway epithelia.  American Journal of Respiratory Cell and Molecular Biology.  61:162-173. 2019
    2019 The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: A case report.  BMC Gastroenterology.  19. 2019
    2019 Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.  Journal of Cystic Fibrosis.  18:536-542. 2019
    2019 Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.  International Forum of Allergy and Rhinology.  9:629-637. 2019
    2019 Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles..  ERJ Open Research.  5. 2019
    2019 Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809 2019
    2019 Colocolonic intussusception in an adult cystic fibrosis patient.  Journal of Cystic Fibrosis.  18:e11-e13. 2019
    2019 Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats.  Mechanisms of Development.  155:15-26. 2019
    2019 Objective versus self-reported adherence to airway clearance therapy in cystic fibrosis 2019
    2019 A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.  JCI insight.  4. 2019
    2019 Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: A cross-sectional study.  Annals of the American Thoracic Society.  16:150-153. 2019
    2019 CFTR modulator theratyping: Current status, gaps and future directions.  Journal of Cystic Fibrosis.  18:22-34. 2019
    2019 Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.  Journal of Cystic Fibrosis.  18:102-109. 2019
    2018 Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.  JCI insight.  3. 2018
    2018 Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice.  Nature Communications.  9. 2018
    2018 The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.  Current Opinion in Pharmacology.  43:152-165. 2018
    2018 Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysema.  JCI insight.  3. 2018
    2018 Functional anatomic imaging of the airway surface.  Annals of the American Thoracic Society.  15:S177-S183. 2018
    2018 VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles.  New England Journal of Medicine.  379:1612-1620. 2018
    2018 VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles.  New England Journal of Medicine.  379:1599-1611. 2018
    2018 Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis.  JCI insight.  3. 2018
    2018 Ataluren, a new therapeutic for alpha-1 antitrypsin-deficient individuals with nonsense mutations.  American Journal of Respiratory and Critical Care Medicine.  198:1099-1102. 2018
    2018 Standardized measurement of nasal membrane transepithelial potential difference (NPD).  Journal of Visualized Experiments.  2018. 2018
    2018 EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis – Study design and patient demographics.  Contemporary Clinical Trials.  72:86-94. 2018
    2018 Maternal smoking induces acquired CFTR dysfunction in neonatal rats.  American Journal of Respiratory and Critical Care Medicine.  198:672-674. 2018
    2018 A revised airway epithelial hierarchy includes CFTR-expressing ionocytes.  Nature.  560:319-324. 2018
    2018 Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): A clinical trial.  American Journal of Respiratory and Critical Care Medicine.  198:526-528. 2018
    2018 An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy.  Molecular Therapy - Methods and Clinical Development.  9:296-304. 2018
    2018 Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvement.  American Journal of Respiratory and Critical Care Medicine.  197:1483-1486. 2018
    2018 Seeing cilia: Imaging modalities for ciliary motion and clinical connections 2018
    2018 Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.  Pediatric Pulmonology.  53:E6-E8. 2018
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway Epithelia.  American Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2018 Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.  BMC Pulmonary Medicine.  18. 2018
    2018 Not simply the lesser of two evils 2018
    2018 Sinus microanatomy and microbiota in a rabbit model of rhinosinusitis.  Frontiers in Cellular and Infection Microbiology.  7. 2018
    2018 Development of an airway mucus defect in the cystic fibrosis rat.  JCI insight.  3. 2018
    2017 Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia.  Scientific Reports.  7. 2017
    2017 Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis.  New England Journal of Medicine.  377:2024-2035. 2017
    2017 Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat.  PLoS ONE.  12. 2017
    2017 Toward inclusive therapy with CFTR modulators: Progress and challenges.  Pediatric Pulmonology.  52:S4-S14. 2017
    2017 Use of ferrets for electrophysiologic monitoring of ion transport.  PLoS ONE.  12. 2017
    2017 Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.  Respiratory Research.  18. 2017
    2017 A multiple reader scoring system for Nasal Potential Difference parameters.  Journal of Cystic Fibrosis.  16:573-578. 2017
    2017 Assessment of acquired mucociliary clearance defects using micro-optical coherence tomography.  International Forum of Allergy and Rhinology.  7:920-925. 2017
    2017 Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.  Human Molecular Genetics.  26:3116-3129. 2017
    2017 The therapeutic potential of CFTR modulators for COPD and other airway diseases.  Current Opinion in Pharmacology.  34:132-139. 2017
    2017 Assessment of ciliary phenotype in primary ciliary dyskinesia by micro-optical coherence tomography..  JCI insight.  2:e91702. 2017
    2017 Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B..  World Journal of Otorhinolaryngology-Head and Neck Surgery.  3:2-8. 2017
    2017 Flexible, high-resolution micro-optical coherence tomography endobronchial probe toward in vivo imaging of cilia.  Optics Letters.  42:867-870. 2017
    2017 A little CFTR can change a lot: slowing cystic fibrosis progression 2017
    2017 Growth in prepubertal children with cystic fibrosis treated with ivacaftor.  Pediatrics.  139. 2017
    2017 Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR.  Annals of the American Thoracic Society.  14:213-219. 2017
    2017 A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis.  Journal of Obstetric, Gynecologic, and Neonatal Nursing.  46:72-77. 2017
    2017 Applying recent advances in the science of CFTR-based therapeutics to improve outcomes in patients with cystic fibrosis.  Journal of Cystic Fibrosis.  2017
    2017 Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation.  Clinical and Translational Gastroenterology.  8. 2017
    2017 The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smoke.  American Journal of Respiratory Cell and Molecular Biology.  56:99-108. 2017
    2017 Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.  Journal of Cystic Fibrosis.  16:24-29. 2017
    2016 Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression 2016
    2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations.  American Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2016 Codon bias and the folding dynamics of the cystic fibrosis transmembrane conductance regulator 2016
    2016 Increasing the endoplasmic reticulum pool of the F508del allele of the cystic fibrosis transmembrane conductance regulator leads to greater folding correction by small molecule therapeutics.  PLoS ONE.  11. 2016
    2016 A ferret model of COPD-related chronic bronchitis.  JCI insight.  1:e87536. 2016
    2016 Particle-Tracking Microrheology Using Micro-Optical Coherence Tomography.  Biophysical Journal.  111:1053-1063. 2016
    2016 Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells.  Cell Stem Cell.  19:217-231. 2016
    2016 Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study 2016
    2016 In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomography.  Biomedical Optics Express.  7:2494-2505. 2016
    2016 Mutation of Growth Arrest Specific 8 Reveals a Role in Motile Cilia Function and Human Disease.  PLoS Genetics.  12. 2016
    2016 Pilot evaluation of ivacaftor for chronic bronchitis 2016
    2016 Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy 2016
    2016 Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in Chronic bronchitis.  Annals of the American Thoracic Society.  13:S169-S176. 2016
    2016 New and emerging targeted therapies for cystic fibrosis.  BMJ.  352. 2016
    2016 Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.  Clinics in Chest Medicine.  37:147-158. 2016
    2016 Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.  Journal of Cystic Fibrosis.  15:67-73. 2016
    2015 Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessation.  American Journal of Respiratory and Critical Care Medicine.  192:1521-1524. 2015
    2015 Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.  Pediatric Pulmonology.  50:S3-S13. 2015
    2015 Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.  Respiratory Medicine.  109:1001-1011. 2015
    2015 Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR.  New England Journal of Medicine.  373:220-231. 2015
    2015 Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial 2015
    2015 Cystic fibrosis.  Nature Reviews Disease Primers.  1:15010. 2015
    2015 ▵F508 CFTR surface stability is regulated by DAB2 and CHIP-mediated ubiquitination in post-endocytic compartments.  PLoS ONE.  10. 2015
    2015 Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.  Chest.  147:e79-e82. 2015
    2015 Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.  Clinical Infectious Diseases.  60:703-712. 2015
    2015 Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs.  American Journal of Respiratory Cell and Molecular Biology.  52:683-694. 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated mice 2015
    2015 Novel outcome measures for clinical trials in cystic fibrosis.  Pediatric Pulmonology.  50:302-315. 2015
    2014 Characterization of defects in ion transport and tissue development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-knockout rats.  PLoS ONE.  9. 2014
    2014 Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data.  Journal of Cystic Fibrosis.  13:139-147. 2014
    2014 Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease.  Respiratory Research.  15. 2014
    2014 Impact of heterozygote CFTR Mutations in COPD patients with Chronic Bronchitis.  Respiratory Research.  15. 2014
    2014 A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial 2014
    2014 A functional anatomic defect of the cystic fibrosis airway.  American Journal of Respiratory and Critical Care Medicine.  190:421-432. 2014
    2014 An autoregulatory mechanism governing mucociliary transport is sensitive to mucus load.  American Journal of Respiratory Cell and Molecular Biology.  51:485-493. 2014
    2014 Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial 2014
    2014 Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.  American Journal of Respiratory and Critical Care Medicine.  190:175-184. 2014
    2014 Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.  American Journal of Respiratory Cell and Molecular Biology.  50:549-558. 2014
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients.  Clinical and Translational Science.  7:336-341. 2014
    2014 Evaluating the predictive ability of sweat chloride.  Journal of Cystic Fibrosis.  13:118. 2014
    2014 Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors.  Molecular Therapy.  22:1484-1493. 2014
    2014 Porcine nasal epithelial cultures for studies of cystic fibrosis sinusitis.  International Forum of Allergy and Rhinology.  4:565-570. 2014
    2014 Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.  American Journal of Respiratory Cell and Molecular Biology.  50:805-816. 2014
    2014 The unfolded protein response affects readthrough of premature termination codons.  EMBO Molecular Medicine.  6:685-701. 2014
    2013 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.  American Journal of Respiratory and Critical Care Medicine.  188:1321-1330. 2013
    2013 Cigarette smoke and CFTR: Implications in the pathogenesis of COPD 2013
    2013 Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR Function.  PLoS ONE.  8. 2013
    2013 Cystic fibrosis chronic rhinosinusitis: A comprehensive review 2013
    2013 IP-10 Is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary Exacerbations.  PLoS ONE.  8. 2013
    2013 Cystic fibrosis transmembrane regulator correctors and potentiators.  Cold Spring Harbor perspectives in biology.  5. 2013
    2013 Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation.  PLoS ONE.  8. 2013
    2013 Cystic fibrosis transmembrane regulator correctors and potentiators.  Cold Spring Harbor perspectives in medicine.  3. 2013
    2013 Cystic fibrosis transmembrane regulator correctors and potentiators.  Cold Spring Harbor perspectives in biology.  5. 2013
    2013 Method for Quantitative Study of Airway Functional Microanatomy Using Micro-Optical Coherence Tomography.  PLoS ONE.  8. 2013
    2013 Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.  Chest.  144:498-506. 2013
    2013 CFTR biomarkers: Time for promotion to surrogate end-point?.  European Respiratory Journal.  41:203-216. 2013
    2013 Comparison of cystic fibrosis transmembrane conductance regulator (CFTR) and ciliary beat frequency activation by the CFTR modulators genistein, VRT-532, and UCCF-152 in primary sinonasal epithelial cultures.  JAMA Otolaryngology-Head and Neck Surgery.  139:822-827. 2013
    2013 Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.  Chest.  144:200-207. 2013
    2013 Understanding the relationship between sweat chloride and lung function in cystic fibrosis.  Chest.  144:1418. 2013
    2012 Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.  Pediatric Pulmonology.  47:1113-1122. 2012
    2012 A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.  PLoS ONE.  7. 2012
    2012 Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator.  Biochemical Journal.  441:633-643. 2012
    2012 CFTR potentiator treatment of cystic fibrosis.  Drugs of the future.  37:167-174. 2012
    2012 Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis 2012
    2012 Progress in cystic fibrosis and the CF Therapeutics Development Network.  Thorax.  67:882-890. 2012
    2012 Purification of CFTR for mass spectrometry analysis: Identification of palmitoylation and other post-translational modifications 2012
    2012 Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.  Thorax.  67:12-18. 2012
    2011 A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.  New England Journal of Medicine.  365:1663-1672. 2011
    2011 Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54 2011
    2011 Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators 2011
    2011 Nasal potential difference measurements to assess CFTR ion channel activity..  Methods in Molecular Biology.  741:69-86. 2011
    2011 Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: Therapeutic implications for chronic rhinosinusitis 2011
    2011 Medicine: A breath of fresh air.  Scientific American.  305:48-53. 2011
    2011 A breath of fresh air..  Scientific American.  305:68-73. 2011
    2010 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.  New England Journal of Medicine.  363:1991-2003. 2010
    2010 Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: Potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue.  American Journal of Respiratory Cell and Molecular Biology.  43:607-616. 2010
    2010 Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens.  Fertility and Sterility.  94:2122-2127. 2010
    2010 Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.  Current Opinion in Pulmonary Medicine.  16:591-597. 2010
    2010 A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation.  Science.  330:90-94. 2010
    2010 An international randomized multicenter comparison of nasal potential difference techniques.  Chest.  138:919-928. 2010
    2010 ΔF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.  Pulmonary Pharmacology and Therapeutics.  23:268-278. 2010
    2010 Proline-Glycine-Proline (PGP) and high mobility group box protein-1 (HMGB1): Potential mediators of cystic fibrosis airway inflammation.  Open Respiratory Medicine Journal.  4:32-38. 2010
    2009 Extensive pulmonary laceration in pediatric trauma.  Respiration: international journal of thoracic medicine.  79:76. 2009
    2009 Pharmaceuticals targeting nonsense mutations in genetic diseases: Progress in development 2009
    2008 Authors' response.  Thorax.  63:1026. 2008
    2008 Potential role of high-mobility group box 1 in cystic fibrosis airway disease.  American Journal of Respiratory and Critical Care Medicine.  178:822-831. 2008
    2008 A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in Chronic neutrophilic inflammation.  Journal of Immunology.  180:5662-5669. 2008
    2008 Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.  Thorax.  63:301-305. 2008
    2008 Authors' response.  Thorax.  63:1027. 2008
    2008 Genetic and reproductive knowledge among adolescents and adults with cystic fibrosis.  Chest.  133:1533. 2008
    2007 Bioelectric effects of quinine on polarized airway epithelial cells.  Journal of Cystic Fibrosis.  6:351-359. 2007
    2007 Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinism.  Clinical Rheumatology.  26:1537-1539. 2007
    2007 Restoration of W1282X CFTR activity by enhanced expression.  American Journal of Respiratory Cell and Molecular Biology.  37:347-356. 2007
    2007 Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.  Annals of the American Thoracic Society.  4:387-398. 2007
    2007 No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.  American Journal of Respiratory Cell and Molecular Biology.  37:57-66. 2007
    2006 Advances in cystic fibrosis therapies.  Current Opinion in Pediatrics.  18:604-613. 2006
    2005 Cystic fibrosis.  New England Journal of Medicine.  352:1992-2001. 2005
    2005 Cystic fibrosis.  New England Journal of Medicine.  352:2039. 2005
    2002 Foodborne disease outbreaks in United States schools 2002
    2000 A foodborne outbreak of gastroenteritis associated with Norwalk-like viruses: First molecular traceback to deli sandwiches contaminated during preparation.  Journal of Infectious Diseases.  181:1467-1470. 2000
    1999 What are the eating cognitions of children whose chronic diseases do and do not require attention to diet?.  Patient Education and Counseling.  36:279-286. 1999

    Research Overview

  • Dr. Rowe specializes in developing new treatments for cystic fibrosis, the most common autosomal recessive genetic disease, and the cause of severe pulmonary disease affecting children and young adults. He founded the CF Transition Clinic for adolescents and young adults with the disease. He maintains expertise in the design and conduct of clinical trials targeting the basic CF defect. Dr. Rowe also has an interest in biomarkers of CF and other related airway diseases including measures of ion transport and the relation between mucus stasis and inflammation. He currently directs a clinical research program that examines the relationship between CF and the chronic bronchitis of COPD.

    Dr. Rowe is an accomplished academic physician scientist- a pioneer in the field of personalized therapeutics for CF, cutting-edge discovery in airway disease biology, and translational research. He is a respected authority in the design and conduct of clinical trials targeting the basic CF defect and has made key advances in the measurement and interpretation of CFTR function in humans and animals. In a related effort, Dr. Rowe has advanced both the molecular and clinical understanding of suppression of premature termination codons, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases.
    Dr. Rowe has recently discovered that COPD patients exhibit acquired CFTR dysfunction through a pathway that causes delayed mucociliary clearance and confers chronic bronchitis. The approach establishes how a single gene in a rare disorder can contribute to the third leading cause of death and has lead to new efforts to evaluate CFTR modulators in patients with chronic bronchitis, potentially leading to a new paradigm for COPD treatment. Dr. Rowe co-invented one-micron resolution optical coherence tomography that captures 3D imaging in real time at the cellular level. The technique is highly sensitive to the epithelial function of airway tissues and can provide simultaneous and non-invasive measurements of the functional microanatomy of the airway surface, significantly advancing our understanding of airway disease pathogenesis.

    • Principal Investigator On

  • Therapeutic Targeting of MUC5B in a Novel Ferret Model of Idiopathic Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2020 - 2024
  • Translational Program in CFTR-Related Airway Diseases  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2023
  • UAB Research and Development Program  awarded by Cystic Fibrosis Foundation ^ 2019 - 2023
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study) (PROMISE-OB-18)  awarded by Cystic Fibrosis Foundation ^ 2018 - 2023
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Admin Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - Engineered PF Phage to treat pseudomonas aeruginosa biofilm infections  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - P&F Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Study)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2018 - 2022
  • Characterizing CFTR Modulated Changes in Sweat Chloride & Clinical Outcomes  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2017 - 2022
  • G551D Observational Study-Expanded to Additional Genotypes and Extended for Long Term Follow-Up (GOAL-e2)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2013 - 2022
  • Cystic Fibrosis Fibrosing Colonopathy Observational (CFFC-OB-11)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2012 - 2022
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2021 - 2022
  • Private Grant  awarded by ELOXX PHARMACEUTICALS 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Consultant for Translational Science  awarded by Cystic Fibrosis Foundation ^ 2014 - 2021
  • Idiopathic Pulmonary Fibrosis, A Disease Initiated by Mucociliary Dysfunction  awarded by UNIVERSITY OF COLORADO DENVER - NEW 2017 - 2021
  • Private Grant  awarded by ELEVEN P15 INC 2019 - 2021
  • Core Center for Measurements of Mucus and Mucociliary Clearance  awarded by Cystic Fibrosis Foundation ^ 2020 - 2021
  • Characterizing CFTR Modulated Changes in Sweat Chloride and Clinical Outcomes  awarded by UNIVERSITY OF COLORADO DENVER - NEW 2017 - 2021
  • The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons  awarded by SOUTHERN RESEARCH INSTITUTE 2015 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2016 - 2021
  • Mucociliary Clearance National Resource Center  awarded by University of North Carolina at Chapel Hill 2020 - 2021
  • UAB Cystic Fibrosis Translational Development Center  awarded by Cystic Fibrosis Foundation ^ 2017 - 2021
  • Private Grant  awarded by TRANSLATE BIO, INC ^ 2019 - 2021
  • Mucus Matters: Mucociliary Physiology in Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2021
  • G551D Observational Study (GOAL-OB-11)  awarded by Cystic Fibrosis Foundation ^ 2011 - 2020
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Mechanism of Aberrant Mucus Adhesion and Stasis in the CF Airways  awarded by Cystic Fibrosis Foundation ^ 2020
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2020
  • Core Center for Measurements of Mucus and Mucociliary Clearance  awarded by Cystic Fibrosis Foundation ^ 2016 - 2020
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2020
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")  awarded by SEATTLE CHILDREN'S HOSPITAL 2014 - 2020
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2020
  • Private Grant  awarded by ASTRAZENECA AB 2016 - 2019
  • TDN Additional Research Coordinator (ARC)  awarded by Cystic Fibrosis Foundation ^ 2014 - 2019
  • Private Grant  awarded by GALAPAGOS NV. 2016 - 2019
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2017 - 2019
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2018 - 2019
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2019
  • Research Development Program  awarded by Cystic Fibrosis Foundation ^ 2015 - 2019
  • Training and Equipment for the MBW sub-study of the PROSPECT Study.  awarded by Cystic Fibrosis Foundation ^ 2014 - 2019
  • A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-Topic)  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2019
  • Private Grant  awarded by ELOXX PHARMACEUTICALS 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA AB 2015 - 2018
  • A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)  awarded by Cystic Fibrosis Foundation ^ 2014 - 2018
  • Private Grant  awarded by GALAPAGOS NV. 2015 - 2018
  • The Mechanism of Tobacco-Induced Decrements in Mucociliary Clearance  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF  awarded by Cystic Fibrosis Foundation ^ 2016 - 2018
  • Private Grant  awarded by ARROWHEAD PHARMACEUTICALS INC. 2017 - 2018
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Admin Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Core C: Clinical & Translational Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Pilot and Feasibility  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • Evaluation of Arina-1 for the Treatment of Cystic Fibrosis Lung Disease  awarded by CYSTIC FIBROSIS FOUNDATION THERAPEUTICS., INC 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by CFD RESEARCH CORPORATION 2016 - 2017
  • An Open Label N of 1 Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Ivacaftor in Combination with ALTALUREN (PTCD124) In Subjects with Nonsense Mutation Cystic Fibrosis  awarded by University of Pennsylvania 2016 - 2017
  • Private Grant  awarded by SYNEDGEN, INC 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2015 - 2017
  • Private Grant  awarded by Bayer HealthCare 2014 - 2017
  • CFTR Functional Restoration by Antisense Oligonucleotides  awarded by Cystic Fibrosis Foundation ^ 2015 - 2017
  • Micro-CT Scanner for Ultra-High Resolution Live Imaging of Large and Small Animals  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2015 - 2017
  • Private Grant  awarded by PULMOTECT 2016 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2017
  • Private Grant  awarded by GALAPAGOS NV. 2014 - 2017
  • Private Grant  awarded by PROGENRA, INC. 2016 - 2017
  • Brevenal Effect on Mucociliary Clearance for Treatment of CF Mucus  awarded by Cystic Fibrosis Foundation ^ 2016 - 2017
  • Effect of PAAG Treatment on CF Related Pseudomonas Infected Respiratory Epithelium  awarded by Cystic Fibrosis Foundation ^ 2016 - 2017
  • Functional Anatomic Imaging of CF Patients with Early Lung Disease Using microOCT  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2014 - 2017
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2016 - 2017
  • Private Grant  awarded by Bayer AG 2014 - 2017
  • Evaluation of Approved Drug Libraries for Translational Readthrough Activity  awarded by Cystic Fibrosis Foundation ^ 2013 - 2017
  • Private Grant  awarded by SYNEDGEN, INC 2015 - 2017
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2016 - 2017
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • UAB Therapeutic Development Network Center  awarded by Cystic Fibrosis Foundation ^ 2015 - 2016
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2014 - 2016
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Private Grant  awarded by ORPRO THERAPEUTICS 2015 - 2016
  • Private Grant  awarded by RAPTOR PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • Mechanistic Link Between Rescue of CFTR Mediated Anion Transport, Airway Surface Liquid Regulation, and Mucociliary Transport by CFTR Modulators  awarded by Cystic Fibrosis Foundation ^ 2010 - 2016
  • Private Grant  awarded by ELOXX PHARMACEUTICALS 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • UAB CF Research and Translation Core Center - Core C  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2016
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • The Mucociliary Clearance Defect of the Cystic Fibrosis Rat  awarded by Cystic Fibrosis Foundation ^ 2014 - 2016
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2013 - 2016
  • Private Grant  awarded by NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2014 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2014 - 2016
  • Private Grant  awarded by Bayer AG 2014 - 2016
  • Therapeutic Development Center - UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^ 2013 - 2015
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance (MCC)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2008 - 2015
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2015
  • The 2015 TDN Spring Meeting  awarded by Cystic Fibrosis Foundation ^ 2015
  • Nasal Epithelial Cells as an Outcome Tool for Individualized CFTR Therapies  awarded by Cystic Fibrosis Foundation ^ 2014 - 2015
  • Private Grant  awarded by SYNEDGEN, INC 2013 - 2015
  • Restoration of the CFTR Function by Splicing Modulation  awarded by Cystic Fibrosis Foundation ^ 2013 - 2015
  • Assessing Response of B-Adrenergic Sweat Secretion in Patients with R117H Mutations Following Treatment with Ivacaftor (GOALe2 Ancillary)  awarded by Cystic Fibrosis Foundation ^ 2014 - 2015
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2013 - 2015
  • Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^ 2013 - 2014
  • Consultant for Translational Science  awarded by Cystic Fibrosis Foundation ^ 2009 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2010 - 2014
  • G551D Observational Study-SEATTLE GOAL  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2012 - 2014
  • Private Grant  awarded by SYNEDGEN, INC 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Systemic CFTR Dysfunction Induced by Acrolein in Cigarette Smoke: A Novel Therapeutic Target for COPD  awarded by American Lung Association 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by DISCOVERY BIOMED, LLC ^ 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2014
  • Individual Project Schedule #6.0  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2011 - 2013
  • Characterization of Novel Translational Readthrough Agents Discovered by High Throughput Screening  awarded by Cystic Fibrosis Foundation ^ 2012 - 2013
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2010 - 2013
  • Genetic Modifiers of Cystic Fibrosis  awarded by Johns Hopkins University 2011 - 2013
  • Development of High Through-Put Screening by SD-OCT in Primary Human Bronchial Epithelial Cells  awarded by FLATLEY DISCOVERY LAB, LLC 2011 - 2013
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2009 - 2013
  • Private Grant  awarded by PTC THERAPEUTICS, INC. 2011 - 2012
  • UAB Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^ 2011 - 2012
  • UAB Cystic Fibrosis Translational Therapeutic Development Center  awarded by Cystic Fibrosis Foundation ^ 2011 - 2012
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2011 - 2012
  • Mechanistic Basis Underlying Protein Repair of CFTR Nonsense Mutations  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2009 - 2012
  • UAB CF Research and Translation Core Center - Core C - Clinical Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2012
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2009 - 2012
  • Private Grant  awarded by HEMAQUEST PHARMACEUTICALS, INC. 2011 - 2012
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2009 - 2011
  • CFF Clinical Fellowship  awarded by Cystic Fibrosis Foundation ^ 2009 - 2011
  • Clinical and Mechanistic Features of Premature Termination Codon Suppression  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2006 - 2011
  • Using Chamber Studies to Characterize CFTR Modulators  awarded by Cystic Fibrosis Foundation ^ 2009 - 2011
  • UAB CF Research and Translation Core Center - Pilot Project 1 - Mucoid Steptococcus Pseumoniae in the CF Lung  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2009

    • Investigator On

  • Pharmacometric Approaches to Precision Optimization of Ivacaftor Response in Cystic Fibrosis Patients  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2020 - 2025
  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • UAB CF Research and Translation Core Center - A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Multicenter Topic Trial).  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2018 - 2023
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2022
  • A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2020 - 2022
  • Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis  awarded by Cystic Fibrosis Foundation ^ 2020 - 2022
  • Dysbiosis of the Sinus Microbiota in Chronic Rhinosinusitis  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2019 - 2022
  • A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN)  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2021 - 2022
  • Private Grant  awarded by ELECTROMED, INC. 2020 - 2021
  • miR-145 Target Site Blockade to Amplify CFTR Correction  awarded by Cystic Fibrosis Foundation ^ 2019 - 2021
  • Overcoming Barriers to F508del CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2021
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2021
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2020 - 2021
  • Exacerbation of Influenza Secondary Infections in Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^ 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Oligotherapeutics to Enhance CFTR Correction  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2019 - 2021
  • Rare CFTR Mutation Cell Collection Protocol (RARE)  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2021
  • Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF  awarded by Cystic Fibrosis Foundation ^ 2020 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2019 - 2021
  • Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2018 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • Novel Therapeutic Approaches for Treatment of CF Patients with W1282X Premature Termination Codon Mutations  awarded by EMILY'S ENTOURAGE 2019 - 2021
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2021
  • UAB Cystic Fibrosis Therapeutic Development Network Center for CFTR Detection  awarded by Cystic Fibrosis Foundation ^ 2016 - 2021
  • Private Grant  awarded by PROTEOSTASIS THERAPEUTICS, INC. 2018 - 2020
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2018 - 2020
  • Standardized Treatment of Pulmonary Exacerbations II  awarded by SEATTLE CHILDREN'S HOSPITAL 2016 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2018 - 2019
  • Losartan as Anti-Inflammatory Therapy to Augment F508del CFTR Recovery  awarded by University of Miami 2017 - 2019
  • MiR-145 Mediated TGF-Beta Pathobiology in CF  awarded by Cystic Fibrosis Foundation ^ 2017 - 2019
  • Private Grant  awarded by PARION SCIENCES, INC. 2016 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2018
  • Private Grant  awarded by ASTRAZENECA AB 2017 - 2018
  • Private Grant  awarded by CELTAXSYS, INC. 2016 - 2018
  • Sweat Gland Culture Techniques for the Study of Cystic Fibrosis  awarded by Cystic Fibrosis Foundation ^ 2015 - 2018
  • Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S HOSPITAL 2013 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2017
  • UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)  awarded by Cystic Fibrosis Foundation ^ 2011 - 2017
  • Private Grant  awarded by Gilead Sciences ^ 2017
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2016 - 2017
  • Private Grant  awarded by PROQR THERAPEUTICS 2015 - 2016
  • Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis  awarded by SEATTLE CHILDREN'S RESEARCH INSTITUTE 2013 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • CFF Yr 3-Reproductive and Sexual Health Care in Young Women with CFF  awarded by University of Pittsburgh The 2015 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2016
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2016
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2015 - 2016
  • Private Grant  awarded by INSMED PHARMACEUTICALS, INC. 2012 - 2016
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2015
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2014 - 2015
  • UAB Research Development Program Component II - Overall Program  awarded by Cystic Fibrosis Foundation ^ 2015
  • Tuning Aminoglycosides for Treatment of Genetic Diseases  awarded by Technion Israel Institute of Technology 2011 - 2015
  • Private Grant  awarded by Gilead Sciences ^ 2012 - 2015
  • Private Grant  awarded by NIVALIS THERAPEUTICS, INC. - NEW 2014 - 2015
  • Private Grant  awarded by FOREST LABORATORIES, INC. 2012 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2013 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • Private Grant  awarded by VERTEX PHARMACEUTICALS, INC. 2012 - 2013
  • Pediatric Cystic Fibrosis Center for Care, Teaching and Research  awarded by Cystic Fibrosis Foundation ^ 2004 - 2013
  • Private Grant  awarded by N30 PHARMACEUTICALS, LLC 2013
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2007 - 2012

    • Education And Training

  • Master of Science in Biostatistics, University of Alabama at Birmingham 2005
  • Doctor of Medicine, Vanderbilt University 1998
  • UAB Hospital, Internship 1999
  • UAB Hospital, Residency 2002
  • UAB Hospital, Postdoctoral Fellowship 2005

    • Full Name

  • Steven Rowe